Showing results (191-200 of 306) with videos related to
Sort By:
Pageof 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factorT Demirer, C D Buckner, B Storer, et al.Bone Marrow Transplantation|August 28, 1998
Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myelomaC H Weaver, B Zhen, L S Schwartzberg, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1988
High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemiaS Riddell, F R Appelbaum, C D Buckner, et al.Bone Marrow Transplantation|February 19, 2002
Economic evaluation of filgrastim, sargramostim, and sequential sargramostim and filgrastim after myelosuppressive chemotherapyC H Weaver, C D Buckner, L H Curtis, et al.Blood|October 1, 1996
Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcomeW I Bensinger, C D Buckner, C Anasetti, et al.Bone Marrow Transplantation|March 1, 1990
Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicityS I Bearman, F B Petersen, R A Schor, et al.Experimental Hematology|September 1, 1993
Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapyZ Pavletic, M C Benyunes, J A Thompson, et al.Bone Marrow Transplantation|June 1, 1996
Factors influencing collection of peripheral blood stem cells in patients with multiple myelomaT Demirer, C D Buckner, T Gooley, et al.Bone Marrow Transplantation|May 1, 1996
High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancerT Demirer, C D Buckner, F R Appelbaum, et al.Bone Marrow Transplantation|August 1, 1993
Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemiaM C Benyunes, C Massumoto, A York, et al.Pageof 31